United Therapeutics (NASDAQ:UTHR) Price Target Raised to $475.00 at UBS Group

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by investment analysts at UBS Group from $415.00 to $475.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price objective would indicate a potential upside of 29.57% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. HC Wainwright upped their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. TD Cowen increased their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 30th. Finally, Jefferies Financial Group increased their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Trading Up 1.2 %

Shares of NASDAQ UTHR opened at $366.61 on Wednesday. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $417.82. The stock has a market cap of $16.37 billion, a P/E ratio of 16.10, a PEG ratio of 1.05 and a beta of 0.57. The business’s fifty day simple moving average is $370.68 and its 200-day simple moving average is $351.87.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.38 earnings per share. On average, equities analysts forecast that United Therapeutics will post 25.22 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,792 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $355.88, for a total transaction of $2,773,016.96. Following the completion of the transaction, the chief financial officer now directly owns 5,884 shares of the company’s stock, valued at $2,093,997.92. This represents a 56.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 142,422 shares of company stock worth $53,498,732 in the last quarter. Company insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ClariVest Asset Management LLC lifted its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter worth $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter valued at $82,000. Finally, Values First Advisors Inc. purchased a new position in shares of United Therapeutics in the third quarter valued at $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.